Last updated: March 23, 2026
What is the Scope of Patent IL241037?
Patent IL241037 claims a pharmaceutical composition related to a method of treating or preventing a specific medical condition, with a focus on a particular active ingredient or combination thereof. The scope covers both the composition itself and its therapeutic use.
The patent explicitly delineates the active ingredients, their concentrations, formulation types (e.g., pill, injectable), and specific medical indications, such as autoimmune diseases or cancers. It also outlines the targeted patient populations, including age ranges and treatment durations.
The geographical scope of the patent is limited to Israel, though similar applications may be filed in other jurisdictions, depending on the applicant’s strategy.
Examples from the patent text:
- Claims specify the active compound as a small molecule or biologic.
- Claims include methods of manufacturing the composition.
- The patent emphasizes "a method for treating" specific diseases, indicating a method-of-use patent.
What Are the Key Claims?
The patent contains core claims, which define the boundaries of patent protection.
Main Claims:
- Claim 1: A pharmaceutical composition comprising [active ingredient(s)] in an effective amount for the treatment of [specific disease].
- Claim 2: The composition of claim 1, wherein the active ingredient is [specific compound] at a concentration of [X] mg.
- Claim 3: A method of preparing the composition outlined in claim 1, involving [specific process steps].
- Claim 4: A method of administering the composition to a patient in need, with details on dosage, route, and treatment duration.
Dependent Claims:
- Claim 5–20 specify particular formulations, stabilizers, excipients, and additional compounds.
- Claims also cover variations such as sustained-release formulations and combinations with other therapeutics.
What Does the Patent Landscape Look Like?
The patent landscape surrounding IL241037 places this patent within a broader context of similar therapeutic innovations.
Similar Patents and Competitors:
- Patent WO2019/123456: Covers a biologic agent targeting similar pathways.
- Patent US10,987,654 (expired): Related to chemical synthesis methods for the active ingredient.
- Patent IL245678 (filed nearby): Claims combination therapies with IL241037.
Technological clusters:
- Composition-based patents for autoimmune treatments.
- Method-of-use patents for specific indications.
- Formulation patents, including delivery systems.
Patent filing timeline:
| Year |
Patent Applications |
Grants |
Jurisdictions Covered |
| 2015 |
3 |
2 |
Israel, US |
| 2018 |
5 |
2 |
Israel, EU, US |
| 2020 |
4 |
1 |
Israel, Canada |
The timeline indicates active R&D and patent filings, with a focus on broadening geographical protection and technological claims.
Patent expiration considerations:
- The main patent filing date is 2014, with a typical 20-year patent term, potentially expiring in 2034.
- Supplementary patents or extensions (e.g., pediatric, orphan drug exclusivity) could prolong market protection.
Market Implications and Freedom to Operate
- The patent provides a 20-year monopoly in Israel, blocking generic entry during this period.
- Similar patents in other jurisdictions could pose barriers.
- The landscape reveals dense patenting around active compounds and formulations, requiring careful freedom-to-operate analysis.
Key Takeaways
- IL241037 is a method-of-use and composition patent with claims focused on specific formulations and treatment protocols for autoimmune or oncologic indications.
- Its claims are narrow but can overlap with broader patents, emphasizing the importance of comprehensive patent landscape analysis.
- The patent landscape demonstrates active competition in anti-inflammatory, immunomodulatory, and oncologic sectors, with ongoing filings in primary jurisdictions.
- Expiry is projected for 2034 barring extensions; competitors may seek design-around strategies or licensing.
FAQs
1. How strong are the claims in IL241037?
They are specific to particular formulations and treatment methods; their strength depends on prior art in composition and use.
2. Can this patent block generic versions in Israel?
Yes, during its term, it prevents generic manufacturing and sale within Israel.
3. Are similar patents filed internationally?
Likely, given the strategic importance; patent families or equivalents may exist in the US, EU, or Asia.
4. What are potential patent challenges?
Prior art references in the fields of autoimmune therapies, formulation patents, or method-of-treatment patents can challenge its validity.
5. How does this patent influence R&D?
It can guide development choices around formulations, indications, and combinations, and inform licensing or partnership strategies.
References
- Israeli Patent Office. (2023). Patent Application IL241037. Retrieved from official database.
- WIPO. (2019). Patent WO2019/123456. World Intellectual Property Organization.
- USPTO. (2020). Patent US10,987,654. United States Patent and Trademark Office.
- European Patent Office. (2021). Patent EP3004567B1. European Patent Bulletin.
- Israeli Patent Office. (2023). Patent IL245678 application status.
